Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NCF1 | P14598 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1673907 | 0.78 | SIRT2 (0.38) | KMT2ANOS1 | |
| SCHEMBL1421802 | 0.74 | NOS1 (0.35) | NOS1 | |
| SCHEMBL3205489 | 0.74 | NOS1 (0.35) | NOS1 | |
| SCHEMBL9996915 | 0.74 | GAA (0.41) | KMT2AGAARAB9ANOS2NOS1 | |
| SCHEMBL5252596 | 0.74 | — | — | |
| SCHEMBL271615 | 0.74 | — | — | |
| SCHEMBL18687434 | 0.71 | TRPA1 (0.31) | — | |
| SCHEMBL17326272 | 0.69 | TRPA1 (0.33) | ROCK1 | |
| SCHEMBL31224907 | 0.69 | — | — | |
| SCHEMBL11086663 | 0.68 | RAB9A (0.43) | KMT2AMEN1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122208-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-20250041451-A1 | GENE THERAPY FOR HEARING LOSS | PERCEIVE BIOTHERAPEUTICS, INC. | 2025-02-06 | — | — | US | disclosed |
| US-20240124492-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2024-04-18 | — | — | US | disclosed |
| US-20240124492-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2024-04-18 | — | — | US | disclosed |
| EP-4319875-A1 | GENE THERAPY FOR HEARING LOSS | Perceive Biotherapeutics, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-111465603-B | Triazolopyridines as gamma secretase modulators | 勃林格殷格翰国际有限公司 | 2024-01-09 | — | — | CN | disclosed |
| EP-3283114-B1 | METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | GALAPAGOS NV (BE) | 2023-09-06 | — | — | EP | disclosed |
| US-11746118-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2023-09-05 | — | — | US | disclosed |
| US-11746118-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2023-09-05 | — | — | US | disclosed |
| WO-2022216845-A1 | GENE THERAPY FOR HEARING LOSS | PERCEIVE BIOTHERAPEUTICS, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| EP-1711498-A2 | 1,2,4-TRIAZOLO¬1,5-A|PYRIDINES AS GASTRIC ACID SECRETION INHIBITORS | Altana Pharma AG (DE) | 2006-10-18 | — | — | EP | disclosed |
| US-20060058320-A1 | [1,2,4] Triazolo[1,5-c]pyrimidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-03-16 | — | — | US | disclosed |
| WO-2005070927-A2 | 1,2,4-TRIAZOLO[1,5-A] PYRIDINES AS GASTRIC ACID SECRETION INHIBITORS | ALTANA PHARMA AG (DE) | 2005-08-04 | — | — | WO | disclosed |
| EP-1544200-A1 | 1,2,4 -TRIAZOLO 1,5-c PYRIMIDINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-06-22 | — | — | EP | disclosed |
| CN-1379777-A | Amino-triazolopyridine derivatives | HOFFMANN LA ROCHE (CH) | 2002-11-13 | — | — | CN | disclosed |
| CN-1379777-A | Amino-triazolopyridine derivatives | HOFFMANN LA ROCHE (CH) | 2002-11-13 | — | — | CN | disclosed |
| US-6355653-B1 | DRUG AND CARRIER FOR ANTIALLERGENS, BRAIN DISORDERS AND NEUROTRANSMITTERS | HOFFMANN-LA ROCHE INC. | 2002-03-12 | — | — | US | disclosed |
| EP-0709722-A1 | Silver halide photographic element and method for stabilizing a light-sensitive silver halide emulsion | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1996-05-01 | — | — | EP | disclosed |
| US-4284713-A | SILVER, SILVER HALIDE OR BINDER IMAGE, MASKING, EXPOSURE, DEVELOPMENT, DECOMPOSITION, ALKALI HALATE OR HALITE, ETCHING | FUJI PHOTO FILM CO., LTD. (JP) | 1981-08-18 | — | — | US | disclosed |
| US-4254214-A | BLACK, REDUCTION OF COPPER SALT OR COMPLEX TO COPPER | FUJI PHOTO FILM CO., LTD. (JP) | 1981-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124492-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | DCK, TYMP, DPYD | KDM4E 836/4885KMT2A 648/4885MEN1 1344/4885 |
| US-20060058320-A1 | [1,2,4] Triazolo[1,5-c]pyrimidine derivatives | ADORA2A, ADORA1, ADORA3 | KDM4E 2955/4885KMT2A 1987/4885MEN1 3652/4885 |
| US-11746118-B2 | Amino-triazolopyridine compounds and their use in treating cancer | DCK, TYMP, DPYD | KDM4E 836/4885KMT2A 648/4885MEN1 1344/4885 |
| US-20250122208-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | ACKR3, CCR5, CXCR3 | KDM4E 4823/4885KMT2A 4697/4885MEN1 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.